Clinical trial
Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma
NCT00005628 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00005628 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma |
| Official title | A Phase II Trial of Active Specific Immunotherapy in Patients With Recurrent Soft Tissue Sarcoma Using Autologous Tumor-derived Heat Shock Protein-Peptide Complex (HSPPC-96) |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Biological |
| Interventions | vitespen |
| Start date | Nov 1, 1999 |
| Primary completion | Aug 1, 2001 |
| Completion | Aug 1, 2001 |
| First posted | Apr 2, 2004 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: